{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T16:06:14Z","timestamp":1779897974963,"version":"3.53.1"},"reference-count":32,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000968","name":"American Heart Association Inc","doi-asserted-by":"publisher","award":["23PRE1019986"],"award-info":[{"award-number":["23PRE1019986"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association Inc","doi-asserted-by":"publisher","award":["24CDA1276922"],"award-info":[{"award-number":["24CDA1276922"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"NHLBI","doi-asserted-by":"publisher","award":["HL007853"],"award-info":[{"award-number":["HL007853"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007270","name":"University of Michigan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007270","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"NIGMS","doi-asserted-by":"publisher","award":["GM131835"],"award-info":[{"award-number":["GM131835"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"NIGMS","doi-asserted-by":"publisher","award":["GM140223"],"award-info":[{"award-number":["GM140223"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001340","name":"W. W. Smith Charitable Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001340","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Vessels, Thrombosis & Hemostasis"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.bvth.2026.100146","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T17:41:44Z","timestamp":1772559704000},"page":"100146","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["VLX-1005, but not argatroban, prevents ITAM-mediated platelet activation and heparin-induced thrombocytopenia"],"prefix":"10.1016","volume":"3","author":[{"given":"Adriana","family":"Yamaguchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Putzbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reheman","family":"Adili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Lazar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6034-0646","authenticated-orcid":false,"given":"Livia","family":"Stanger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devin","family":"Gilmore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Maloney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven E.","family":"McKenzie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8796-5259","authenticated-orcid":false,"given":"James V.","family":"Michael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5100-1933","authenticated-orcid":false,"given":"Michael","family":"Holinstat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"22","key":"10.1016\/j.bvth.2026.100146_bib1","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1182\/bloodadvances.2018024489","article-title":"American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia","volume":"2","author":"Cuker","year":"2018","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.bvth.2026.100146_bib2","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1080\/17474086.2021.1905512","article-title":"Heparin-induced thrombocytopenia: pathophysiology, diagnosis and treatment","volume":"14","author":"Hvas","year":"2021","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.bvth.2026.100146_bib3","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.trsl.2020.04.014","article-title":"Pathogenesis of heparin-induced thrombocytopenia","volume":"225","author":"Arepally","year":"2020","journal-title":"Transl Res"},{"issue":"2","key":"10.1016\/j.bvth.2026.100146_bib4","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1001\/archsurg.1958.01280200041005","article-title":"Arterial embolism occurring during systemic heparin therapy","volume":"76","author":"Weismann","year":"1958","journal-title":"AMA Arch Surg"},{"issue":"1","key":"10.1016\/j.bvth.2026.100146_bib5","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1055\/s-0038-1656329","article-title":"Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia","volume":"68","author":"Amiral","year":"1992","journal-title":"Thromb Haemost"},{"issue":"1","key":"10.1016\/j.bvth.2026.100146_bib6","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1172\/JCI116987","article-title":"Antibodies from patients with heparin-induced thrombocytopenia\/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells","volume":"93","author":"Visentin","year":"1994","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1016\/j.bvth.2026.100146_bib7","first-page":"247","article-title":"Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen","volume":"71","author":"Greinacher","year":"1994","journal-title":"Thromb Haemost"},{"issue":"11","key":"10.1016\/j.bvth.2026.100146_bib8","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.1182\/blood.V83.11.3232.3232","article-title":"Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4","volume":"83","author":"Kelton","year":"1994","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.bvth.2026.100146_bib9","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1182\/blood-2011-11-376293","article-title":"How I treat heparin-induced thrombocytopenia","volume":"119","author":"Cuker","year":"2012","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.bvth.2026.100146_bib10","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1161\/01.CIR.103.14.1838","article-title":"Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia","volume":"103","author":"Lewis","year":"2001","journal-title":"Circulation"},{"issue":"14","key":"10.1016\/j.bvth.2026.100146_bib11","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1182\/blood-2014-05-575878","article-title":"Platelet 12-LOX is essential for Fc\u03b3RIIa-mediated platelet activation","volume":"124","author":"Yeung","year":"2014","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.bvth.2026.100146_bib12","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1161\/ATVBAHA.117.309868","article-title":"First selective 12-LOX inhibitor, ML355, impairs thrombus formation and vessel occlusion in vivo with minimal effects on hemostasis","volume":"37","author":"Adili","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"10.1016\/j.bvth.2026.100146_bib13","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1111\/jth.15184","article-title":"DHA 12-LOX-derived oxylipins regulate platelet activation and thrombus formation through a PKA-dependent signaling pathway","volume":"19","author":"Yamaguchi","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"18","key":"10.1016\/j.bvth.2026.100146_bib14","doi-asserted-by":"crossref","first-page":"4522","DOI":"10.1182\/bloodadvances.2020002493","article-title":"Omega-6 DPA and its 12-lipoxygenase-oxidized lipids regulate platelet reactivity in a nongenomic PPAR\u03b1-dependent manner","volume":"4","author":"Yeung","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.bvth.2026.100146_bib15","series-title":"VLX-1005 multiple ascending dose pharmacokinetics","author":"Henry","year":"2024"},{"issue":"5","key":"10.1016\/j.bvth.2026.100146_bib16","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1182\/blood.V95.5.1533.005k01_1533_1540","article-title":"Characterization of a murine monoclonal antibody that mimics heparin-induced thrombocytopenia antibodies","volume":"95","author":"Arepally","year":"2000","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.bvth.2026.100146_bib17","doi-asserted-by":"crossref","first-page":"4254","DOI":"10.1182\/blood.V96.13.4254","article-title":"Thrombosis and shock induced by activating antiplatelet antibodies in human Fc gamma RIIA transgenic mice: the interplay among antibody, spleen, and Fc receptor","volume":"96","author":"Taylor","year":"2000","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.bvth.2026.100146_bib18","doi-asserted-by":"crossref","first-page":"4311","DOI":"10.4049\/jimmunol.162.7.4311","article-title":"The role of the human Fc receptor Fc gamma RIIA in the immune clearance of platelets: a transgenic mouse model","volume":"162","author":"McKenzie","year":"1999","journal-title":"J Immunol"},{"issue":"7","key":"10.1016\/j.bvth.2026.100146_bib19","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1182\/blood-2010-03-274969","article-title":"PRT-060318, a novel Syk inhibitor, prevents heparin-induced thrombocytopenia and thrombosis in a transgenic mouse model","volume":"117","author":"Reilly","year":"2011","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.bvth.2026.100146_bib20","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1161\/ATVBAHA.123.319434","article-title":"Novel strategy to combat the procoagulant phenotype in heparin-induced thrombocytopenia using 12-LOX inhibition","volume":"43","author":"Renna","year":"2023","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"49","key":"10.1016\/j.bvth.2026.100146_bib21","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abd0130","article-title":"Synthetic high-density lipoproteins loaded with an antiplatelet drug for efficient inhibition of thrombosis in mice","volume":"6","author":"He","year":"2020","journal-title":"Sci Adv"},{"key":"10.1016\/j.bvth.2026.100146_bib22","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.thromres.2017.04.005","article-title":"Blood clot parameters: thromboelastography and scanning electron microscopy in research and clinical practice","volume":"154","author":"Pretorius","year":"2017","journal-title":"Thromb Res"},{"issue":"1","key":"10.1016\/j.bvth.2026.100146_bib23","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1172\/JCI122955","article-title":"Functional significance of the platelet immune receptors GPVI and CLEC-2","volume":"129","author":"Rayes","year":"2019","journal-title":"J Clin Invest"},{"issue":"4","key":"10.1016\/j.bvth.2026.100146_bib24","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1182\/blood-2011-03-342352","article-title":"CalDAG-GEFI deficiency protects mice in a novel model of Fc\u03b3 RIIA-mediated thrombosis and thrombocytopenia","volume":"118","author":"Stolla","year":"2011","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bvth.2026.100146_bib25","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1124\/pr.117.014530","article-title":"Platelet signaling and disease: targeted therapy for thrombosis and other related diseases","volume":"70","author":"Yeung","year":"2018","journal-title":"Pharmacol Rev"},{"issue":"12","key":"10.1016\/j.bvth.2026.100146_bib26","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1161\/01.RES.0000132281.78948.65","article-title":"Platelet 12-lipoxygenase activation via glycoprotein VI: involvement of multiple signaling pathways in agonist control of H(P)ETE synthesis","volume":"94","author":"Coffey","year":"2004","journal-title":"Circ Res"},{"issue":"8","key":"10.1016\/j.bvth.2026.100146_bib27","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/ajh.24759","article-title":"Clinical outcomes in a cohort of patients with heparin-induced thrombocytopenia","volume":"92","author":"Kuter","year":"2017","journal-title":"Am J Hematol"},{"issue":"5-6","key":"10.1016\/j.bvth.2026.100146_bib28","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1046\/j.1440-1681.2001.03468.x","article-title":"Dynamic aspects of platelet adhesion under flow","volume":"28","author":"Dopheide","year":"2001","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"26","key":"10.1016\/j.bvth.2026.100146_bib29","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1182\/blood-2017-04-780825","article-title":"Platelet interaction with activated endothelium: mechanistic insights from microfluidics","volume":"130","author":"Coenen","year":"2017","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.bvth.2026.100146_bib30","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1161\/ATVBAHA.116.307979","article-title":"TULA-2 (T-cell ubiquitin ligand-2) inhibits the platelet Fc receptor for IgG IIA (Fc\u03b3RIIA) signaling pathway and heparin-induced thrombocytopenia in mice","volume":"36","author":"Zhou","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"suppl 1","key":"10.1016\/j.bvth.2026.100146_bib31","doi-asserted-by":"crossref","first-page":"S313","DOI":"10.1111\/jth.12947","article-title":"Antiplatelet drugs: which targets for which treatments?","volume":"13","author":"Gachet","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"1","key":"10.1016\/j.bvth.2026.100146_bib32","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1023\/A:1015368126304","article-title":"Argatroban","volume":"13","author":"Kathiresan","year":"2002","journal-title":"J Thromb Thrombolysis"}],"container-title":["Blood Vessels, Thrombosis & Hemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950327226000112?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950327226000112?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T15:21:44Z","timestamp":1779895304000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950327226000112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S2950327226000112"],"URL":"https:\/\/doi.org\/10.1016\/j.bvth.2026.100146","relation":{},"ISSN":["2950-3272"],"issn-type":[{"value":"2950-3272","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"VLX-1005, but not argatroban, prevents ITAM-mediated platelet activation and heparin-induced thrombocytopenia","name":"articletitle","label":"Article Title"},{"value":"Blood Vessels, Thrombosis & Hemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bvth.2026.100146","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100146"}}